Publication & Citation Trends
Most Cited Works
Publications
14 total
Abstract 1758: ATX-559, a first in class DHX9 inhibitor, and targeted therapeutic for molecularly defined tumors with genomic instability and replicative stress
Cited by 1
OpenAlex
Characterization of exoribonuclease XRN1 as a cancer target and identification of adenosine-3’,5’-bisphosphate as a potent enzyme inhibitor PDF
Cited by 1
OpenAlex
Abstract PR003: DHX9 inhibition as a novel therapeutic for ovarian and breast cancer with loss-of-function mutations in the DNA damage repair genes BRCA1 or BRCA2
Cited by 1
OpenAlex
Abstract 3908: DHX9 inhibition as a novel therapeutic for cancer with loss-of-function mutations in DNA damage repair genes BRCA1 and BRCA2
Cited by 0
OpenAlex
Abstract SY11-02: Small molecule inhibitors of RNA modifying enzymes as precision cancer therapeutics
Cited by 0
OpenAlex
Integrated analysis of single-cell chromatin state and transcriptome identified common vulnerability despite glioblastoma heterogeneity PDF
Cited by 27
OpenAlex
Abstract C087: DHX9 inhibition as a novel therapeutic modality in microsatellite instable colorectal cancer
Cited by 0
OpenAlex
Research Topics
Cancer Genomics and Diagnostics
(4)
RNA modifications and cancer
(4)
Glioma Diagnosis and Treatment
(2)
DNA and Nucleic Acid Chemistry
(2)
CRISPR and Genetic Engineering
(2)
Frequent Co-Authors
Affiliations
Harvard University
Harvard University Press
University of California, San Diego
Accent Therapeutics (United States)
Ludwig Cancer Research